Identification of methylation-silenced genes in colorectal cancer cell lines: Genomic screening using oligonucleotide arrays

Scandinavian Journal of Gastroenterology

Volumn 42, Issue 12, 2007, Pages 1486-1494

  Fukutomi, Satoshi ^a   Seki, Naohiko ^a   Koda, Keiji ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 aza 2 deoxycytidine; Colorectal cancer; Methylation; Oligonucleotide microarray; Silencing; UCHL1

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

AGED; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DNA MICROARRAY; GAGE7 GENE; GAGED2 GENE; GENE; GENE IDENTIFICATION; GENE SILENCING; GENETIC SCREENING; GENOME; HUMAN; HUMAN CELL; HUMAN TISSUE; MAEL GENE; METHYLATION; NUCLEOTIDE SEQUENCE; PAGE 5 GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; UCHL1 GENE; UPREGULATION; VCX GENE;

AGED; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; UBIQUITIN THIOLESTERASE;

EID: 36249026236     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701491173     Document Type: Article

References (37)

1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
2. White RL. Tumor suppressing pathways. Cell 1998;92:591-2.
3. Peltomaki P, de la Chapelle A. Mutations predisposing to hereditary nonpolyposis colorectal cancer. Adv Cancer Res 1997;71:93-119.
4. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
5. Jones PA. The DNA methylation paradox. Trends Genet 1999;15:34-7.
6. Deng G, Chen A, Hong J, Chae HS, Kim YS. Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res 1999;59:2029-33.
7. Esteller M, Sparks A, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:4366-71.
8. Robertson KD, Jones PA. DNA methylation: past, present and future directions. Carcinogenesis 2000;21:461-7.
9. Xiong Z, Wu AH, Bender CM, Tsao JL, Blake C, Shibata D, et al. Mismatch repair deficiency and CpG island hypermethylation in sporadic colon adenocarcinomas. Cancer Epidemiol Biomark Prev 2001;10:799-803.
10. Herman JG. Hypermethylation pathways to colorectal cancer. Implications for prevention and detection. Gastroenterol Clin North Am 2002;31:945-58.
11. Sanchez-Cespedes M, Esteller M, Hibi K, Cope FO, Westra WH, Piantadosi S, et al. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence. Clin Cancer Res 1999;5:2450-4.
12. Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002;2:210-9.
13. Jones PA. DNA methylation errors and cancer. Cancer Res 1996;56:2463-7.
14. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002;196:1-7.
15. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-54.
16. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002;31:141-9.
17. Mandelker DL, Yamashita K, Tokumaru Y, Mimori K, Howard DL, Tanaka Y, et al. PGP9.5 promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005;65:4963-8.
18. Tokumaru Y, Yamashita K, Osada M, Nomoto S, Sun DI, Xiao Y, et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004;64:5982-7.
19. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, et al. Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004;64:4442-52.
20. Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987;196:261-82.
21. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32.
22. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003;194:272-88.
23. Brinkmann U, Vasmatzis G, Lee B, Pastan I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 1999;59:1445-8.
24. Wang T, Fan L, Watanabe Y, McNeill P, Fanger GR, Persing DH, et al. L552S, an alternatively spliced isoform of XAGE-1, is over-expressed in lung adenocarcinoma. Oncogene 2001;20:7699-709.
25. Lim JH, Kim S-P, Gabrielson E, Park YB, Park JW, Kwon tK. Int J Cancer 2005;116:200-6.
26. Chen ME, Lin SH, Chung LWK, Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. J Biol Chem 1988;273:17618-25.
27. Okochi-Takada E, Nakazawa K, Wakabayashi M, Mori A, Ichimura S, Yasugi T, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer 2006;119:1338-44.
28. Wilkinson K, Lee K, Deshpande S, Duerksen-Hughes P, Boss J, Pohl J. The neuron-specific protein PGP9.5 is a ubiquitin carboxy-terminal hydrolase. Science 1989;246:670-3.
29. Liu Y, Fallon L, Lashuel H, Liu Z, Lansbury P Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect a-synuclein degradation and Parkinson's disease susceptibility. Cell 2002;111:209-18.
30. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, et al. The ubiquitin pathway in Parkinson's disease. Nature 1998;395:451-2.
31. Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 1999;23:47-51.
32. Tezel E, Hibi K, Nagasaka T, Nakao A. PGP9.5 as a prognostic factor in pancreatic cancer. Clin Cancer Res 2000;6:4764-7.
33. Takase T, Hibi K, Yamazaki T, Nakayama H, Taguchi M, Kasai Y, et al. PGP9.5 overexpression in esophageal squamous cell carcinoma. Hepatogastroenterol 2003;50:1278-80.
34. Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, John L, et al. Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Res 2003;63:3735-42.
35. Diana LM, Yamashita K, Tokumaru Y, Mimori K, David LH, Tanaka Y, et al. PGP9.5 Promoter methylation is an independent prognostic factor for esophageal squamous cell carcinoma. Cancer Res 2005;65:4963-8.
36. Yamazaki T, Hibi K, Takase T, Tezel E, Nakayama H, Kasai Y, et al. PGP9.5 as a marker for invasive colorectal cancer. Clin Cancer Res 2002;8:192-5.
37. Leibovitz A, Stinson JC, McCombs WB, MeCoy CE, Mazur KC, Mabry ND. Classification of human colorectal adenocarcinoma cell lines. Cancer Res 1976;36:4562-9.